THE INFLUENCE OF TISSUE ANGIOTENSINS ON ELEMENTS OF THE CARDIOVASCULAR SYSTEM (LECTURE 2)

Relevance. One of the main causes of death according to the World Health Organization is cardiovascular diseases. It is well known that dysregulation and/or overexpression of elements of the renin-angiotensin system leads to many negative vascular effects, thereby contributing to the development of cardiovascular diseases and pathological processes, including hypertension, aneurysms, congestive heart failure, stroke, coronary heart disease and endothelial dysfunction.

Aim. To consider the main angiotensins and the mechanisms of their action on vascular tone, endothelial functioning, and myocardial function. To demonstrate the participation of the renin-angiotensin system in the formation of the main types of cardiovascular pathology.

Results. The lecture discusses the cardiogenic and vascular effects of angiotensins II, 1-7, 1-9 and the role of these angiotensins in the development of atherosclerosis, coronary heart disease, heart failure, and arterial hypertension. The article presents the main principles of correction of the angiotensin system disorder and promising directions of research of this problem.

Conclusion. The concept of the classical renin-angiotensin system regulating arterial pressure and vascular tone has evolved into the understanding of this system as a complex network of mediators-anti-tensins and their receptors affecting many physiological pathways.

Although the main components of the renin-angiotensin system were discovered more than half a century ago, this system still attracts a large number of researches works in various fields. The renin-angiotensin-aldosterone system has a number of regulatory and counter-regulatory axes that have a significant impact on the course of many diseases. Among the numerous options for cardiovascular therapy used to treat hypertension and heart failure, drugs that affect the renin-angiotensin-aldosterone system play a significant therapeutic role.

1. World Health Organization: global website. Available at: https://www.who.int/ru [accessed: 17.06.2024].

2. World Health Organization: global website. Cardiovascular diseases. Available at: https://www.who.int/ru/health-topics/cardiovascular-diseases#tab=tab_1 [accessed: 17.06.2024].

3. Capric V., Priyan Chandrakumar H., Celenza-Salvatore J.N., Makaryus A. The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications [Internet]. Renin-Angiotensin Aldosterone System. IntechOpen; 2021. Available from: DOI:10.5772/intechopen.96415

4. Paul M., Poyan Mehr A., Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803. DOI:10.1152/physrev.00036.2005

5. Ahmad S., Ferrario C.M. Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018). Expert Opin Ther Pat. 2018;28(11):755-764. DOI:10.1080/13543776.2018.1531848

6. Froogh G., Pinto J.T., Le Y. et al. Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol. 2017;312(2):H223-H231. DOI:10.1152/ajpheart.00534.2016

7. Sun Y., Weber K.T. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med. 1996;127(1):94-101. DOI:10.1016/s0022-2143(96)90170-5

8. Martyniak A., Tomasik P.J. A New Perspective on the Renin-Angiotensin System. Diagnostics (Basel). 2022;13(1):16. DOI:10.3390/diagnostics13010016

9. Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8

10. Turner A.J., Nalivaeva N.N. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022;151:170766. DOI:10.1016/j.peptides.2022.170766

11. Hilgers K.F., Kuczera M., Wilhelm M.J. et al. Angiotensin formation in the isolated rat hindlimb. J Hypertens. 1989;7(10):789-798. DOI:10.1097/00004872-198910000-00004

12. Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88. DOI:10.1080/08037050310001057

13. Hrenak J., Paulis L., Simko F. Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology. Int J Mol Sci. 2016;17(7):1098. DOI:10.3390/ijms17071098

14. van Thiel B.S., van der Pluijm I., te Riet L. et al. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763(Pt A):3-14. DOI:10.1016/j.ejphar.2015.03.090

15. Le NA. Lipoprotein-associated oxidative stress: a new twist to the postprandial hypothesis. Int J Mol Sci. 2014;16(1):401-19. DOI:10.3390/ijms16010401

16. Romero J.C., Reckelhoff J.F. Role of Angiotensin and Oxidative Stress in Essential Hypertension. Hypertension. 1999;34(4):943-949. DOI:10.1161/01.HYP.34.4.943

17. Fang C., Schmaier A.H. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems. Pharmacol Res. 2020;160:105096. DOI:10.1016/j.phrs.2020.105096

18. Paz Ocaranza M., Riquelme J.A., García L. et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. DOI:10.1038/s41569-019-0244-8

19. Flores-Monroy J., Lezama-Martínez D., Martínez-Aguilar L. Function of renin angiotensin system on heart failure. Journal of Integrative Cardiology. 2016;2(5):380-386. DOI:10.15761/JIC.1000180

20. Zhong J., Basu R., Guo D. et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-728. DOI:10.1161/CIRCULATIONAHA.110.955369.

21. Kibel A, editor. Selected Chapters from the Renin-Angiotensin System [Internet]. IntechOpen; 2020. Available from: http://dx.doi.org/10.5772/intechopen.77666

22. Харкевич Д.А. Фармакология. М.:ГЭОТАР-Медиа; 2021. [Kharkevich D.A. Pharmacology. M.:GEOTAR-Media; 2021 (In Russian)].

23. Cruz-López E.O., Ye D., Wu C. et. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension. 2022;79(10):2115-2126. DOI:10.1161/HYPERTENSIONAHA.122.18731

24. Pantzaris N.D., Karanikolas E., Tsiotsios K., Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J Clin Med. 2017;6(6):61. DOI:10.3390/jcm6060061